Destiny Pharma PLC Exercise of Options (0945S)
07 March 2019 - 5:00AM
UK Regulatory
TIDMDEST
RNS Number : 0945S
Destiny Pharma PLC
06 March 2019
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Exercise of Options
Brighton, United Kingdom - 6 March 2019 - Destiny Pharma (AIM:
DEST), a clinical stage biotechnology company focused on the
development of novel antimicrobial drugs, that addresses the global
problem of antimicrobial resistance (AMR), today announces that it
has issued 127,597 new ordinary shares of 1 pence each in the
capital of the Company (the "New Ordinary Shares") following an
exercise of share options by a former employee.
Application will be made to the London Stock Exchange for the
New Ordinary Shares to be admitted to trading on AIM, with dealings
expected to commence on 13 March 2019 ("Admission").
Following Admission, the Company will have a total of 43,690,195
Ordinary Shares in issue. Shareholders may use this figure of
43,690,195 Ordinary Shares as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of
the Company under the FCA's Disclosure Guidance and Transparency
Rules.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell
destinypharma@fticonsulting.com
+44 (0) 20 3727 1000
Cantor Fitzgerald Europe (Nominated Adviser and Joint
Broker)
Philip Davies / Will Goode, Corporate Finance
Andrew Keith, Healthcare Equity Sales
+44 (0)20 7894 7000
finnCap Ltd (Joint Broker)
Geoff Nash /Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative
biotechnology company focused on the development of novel medicines
from its XF platform that represent a new approach to the treatment
of infectious disease. These potential new medicines are being
developed to address the need for new drugs for the prevention and
treatment of life-threatening infections caused by
antibiotic-resistant bacteria, often referred to as "superbugs".
Tackling anti-microbial resistance has become a global imperative
recognised by the WHO and the United Nations, as well as the G7 and
the G20 countries. For further information, please visit
https://www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEKMGGFNVNGLZM
(END) Dow Jones Newswires
March 06, 2019 13:00 ET (18:00 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024